Assessment of Anatomical and Functional Outcomes in Subjects Treated With Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)
Phase of Trial: Phase IV
Latest Information Update: 18 Jan 2017
At a glance
- Drugs Ocriplasmin (Primary)
- Indications Eye disorders
- Focus Therapeutic Use
- Sponsors Alcon
- 24 May 2016 Status changed from active, no longer recruiting to completed.
- 30 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
- 30 Mar 2016 Planned primary completion date changed from 1 Jun 2016 to 1 May 2016 as reported by ClinicalTrials.gov.